Precision Optical Guidance for Oral Biopsy
ConditionOral Lesions
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorM.D. Anderson Cancer Center
About this trial
To learn if a new type of imaging device called the Active Biopsy Guidance System can help doctors to decide when and where to perform invasive biopsies of mouth lesions.
Eligibility criteria
Qualifiers
Adult subjects with clinically evident oral lesions such as leukoplakia or erythroplakia, oral potentially malignant disorders (OPMD) such as lichen planus and graft vs. host disease, pathologic diagnosis of dysplasia, squamous cell carcinoma, or a history of resected oral cancer, are eligible to participate. Patients with previous treatment including surgery, radiation, chemotherapy or other therapies are also eligible.
Ability to understand and willingness to sign a written Informed Consent Document (ICD).
Disqualifiers
Known allergy to proflavine or acriflavine.
Age less than 18 years.
Pregnant or nursing females.
Adults unable to consent
Trial design
Treatments tested in this trial
- High Resolution Microendoscope (HRME)
- Optical Mapping Scope
- Proflavine hemisulfate
Treatment groups
90 Participants
are divided into 1 treatment groupSponsors and collaborators
M.D. Anderson Cancer Center
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
Collaborator
Source ClinicalTrials.gov